Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

to connected objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
In: Kreis, K.; Horenkamp-Sonntag, D.; Schneider, U.; Zeidler, J.; Glaeske, G. et al.: Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer. In: BJU international : the journal of the British Association of Urological Surgeons, the European Society of Paediatric Urology and the Societé Internationale d'Urologie 129 (2022), Nr. 4, S. 470-479. DOI: https://doi.org/10.1111/bju.15542

Event
Veröffentlichung
(where)
Hannover
(who)
Gottfried Wilhelm Leibniz Universität Hannover
(when)
2021
Event
Veröffentlichung
(where)
Hannover
(who)
Technische Informationsbibliothek (TIB)
(when)
2021
Creator
Kreis, Kristine
Horenkamp-Sonntag, Dirk
Schneider, Udo
Zeidler, Jan
Glaeske, Gerd
Weissbach, Lothar

DOI
10.15488/12877
URN
urn:nbn:de:101:1-2022102702111006186346
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
25.03.2025, 1:48 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Kreis, Kristine
  • Horenkamp-Sonntag, Dirk
  • Schneider, Udo
  • Zeidler, Jan
  • Glaeske, Gerd
  • Weissbach, Lothar
  • Gottfried Wilhelm Leibniz Universität Hannover
  • Technische Informationsbibliothek (TIB)

Time of origin

  • 2021

Other Objects (12)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.

Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer

Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer

Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis

Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis

Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis

Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis

Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement

Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement

Related objects